Clinical Trial Update: Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 [Phase 4]

View source ↗

Summary

Phase 4 trial update on converting from standard phosphate binder therapy to Fosrenol (lanthanum carbonate) in chronic kidney disease stage 5; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• FOSRENOL (lanthanum carbonate)

Snippet

Sponsor: Shire | Conditions: Kidney Diseases | Phase 4 | Status: TERMINATED